UTHEVER® NMN: The Only NMN to Receive EFSA Positive Safety Opinion for Novel Food
July 2026
Access the UTHEVER® NMN white paper to discover this anti-ageing ingredient’s technical advantages & official compliance documents, including FDA NDI clearance in the U.S. and a positive EFSA safety opinion in Europe – the first-ever EU official safety endorsement for NMN. Learn the recommended safe daily intake of NMN as assessed by regulatory authorities in the white paper. Next, UTHEVER® NMN will be added to the EU Novel Food list, helping brands accelerate early market entry with strong regulatory support.
This Technical Paper is brought to you by EffePharm Ltd.
Brain & Mental Health
Clinical trial challenges omega-3 claims for cognitive function and Alzheimer’s risk
A study has found that omega-3 fish oil supplementation does not provide any meaningful benefits for memory, cognition, or brain changes related to Alzheimer’s disease. Even though supplementing with fish oil provides the...
Brain & Mental Health
Brain health supplements shift from generic support to mechanism-driven cognitive solutions
The nutrition industry is increasingly recognizing the interconnectedness of cognition and other areas, such as gut, eye, and metabolic health, alongside longevity and mental well-being. Meanwhile, consumer expectations have...
Brain & Mental Health
Can creatine treat depression? Review reveals mixed findings
A scientific literature review has found mixed results in creatine monohydrate’s potential to treat major depressive disorder (MDD), suggesting it could serve as an adjunct treatment. However, the evidence is not settled....
